Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for debilitating diseases with significant unmet medical need, particularly cardiovascular and autoinflammatory conditions. Its commercial product, ARCALYST, is an interleukin-1 alpha and beta cytokine trap approved in the United States to treat recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes, and Deficiency of Interleukin-1 Receptor Antagonist. The company delivers ARCALYST to patients through a network of specialty pharmacies, while advancing investigational clinical candidates such as KPL-387 for recurrent pericarditis and preclinical programs like KPL-1161.

The company markets its approved therapy throughout the United States, utilizing a specialized internal salesforce. Beyond the United States, it holds worldwide rights to ARCALYST excluding the Middle East and North Africa, having granted development and commercialization rights in the Asia-Pacific territory excluding Japan to a regional partner. The company operates an internal facility to manufacture drug substance for research and early-stage development, while relying on third-party contract manufacturers for late-stage and commercial drug supply. Headquarter details are not stated in the text.

Summary of the business section of Kiniksa Pharmaceuticals International's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 366 full-time employees, of which 351 were located within the United States and 15 were located outside of the United States.”